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Abstract
Context: Prostate biopsy is commonly performed for cancer detection andmanagement.
The benefits and risks of prostate biopsy are germane to ongoing debates about prostate
cancer screening and treatment.
Objective: To perform a systematic review of complications from prostate biopsy.
Evidence acquisition: A literature search was performed using PubMed and Embase,
supplemented with additional references. Articles were reviewed for data on the
following complications: hematuria, rectal bleeding, hematospermia, infection, pain,
lower urinary tract symptoms (LUTS), urinary retention, erectile dysfunction, and
mortality.
Evidence synthesis: After biopsy, hematuria and hematospermia are common but
typically mild and self-limiting. Severe rectal bleeding is uncommon. Despite antimi-
crobial prophylaxis, infectious complications are increasing over time and are the most
common reason for hospitalization after biopsy. Pain may occur at several stages of
prostate biopsy and can be mitigated by anesthetic agents and anxiety-reduction
techniques. Up to 25% of men have transient LUTS after biopsy, and <2% have frank
urinary retention, with slightly higher rates reported after transperineal template
biopsy. Biopsy-related mortality is rare.
Conclusions: Preparation for biopsy should include antimicrobial prophylaxis and pain
management. Prostate biopsy is frequently associated with minor bleeding and urinary
symptoms that usually do not require intervention. Infectious complications can be
serious, requiring prompt management and continued work into preventative strategies.
ed by Elsevier B.V. on behalf of European Association of Urology.
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Transrectal ultrasound–guided prostate biopsy (TRUS-Bx)
is one of the most common urological procedures, with
>1 million procedures performed per year in Europe
and the United States. The indications for prostate biopsy
include a suspicious digital rectal examination and elevated0302-2838/$ – see back matter Published by Elsevier B.V. on behalf of Euro
http://dx.doi.org/10.1016/j.eururo.2013.05.049prostate-specific antigen (PSA) level, often considered in the
context of other risk factors such as age, race, PSA velocity,
and comorbidities [1]. Biopsy is typicallywell tolerated, with
a low risk ofmajor complications. However,minor complica-
tions such as pain and bleeding are frequent [2], and
infectious complications have increased over time [3,4]. Our
objective was to perform a systematic review of TRUS-Bxpean Association of Urology.
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urinary tract symptoms (LUTS), urinary retention, erectile
dysfunction (ED), andmortality. In addition,we reviewed the
complications of transperineal biopsies.
2. Evidence acquisition
First, we performed PubMed and Embase searches for all
English-language publications from 2002 to January 2013
with the search terms prostate biopsy AND complications.
This search identified 4818 records, which were reviewed
by title or abstract. An additional 40 unique records were
identified through hand searches, discussion with
experts, and secondary searches, including the Web of
Science, using the search terms erections OR erectile
function or erectile dysfunction AND prostate biopsy as well
as transperineal AND prostate biopsy. Figure 1 shows a
flowchart of the search process. A total of 213 unique
references from this search were included in the
qualitative synthesis.
3. Evidence synthesis
3.1. Bleeding
One of the most frequent and bothersome complications of
TRUS-Bx is bleeding [5], such as hematuria, hematospermia
or hemoejaculate, and hematochezia, or rectal bleeding. In
[(Fig._1)TD$FIG]
Fig. 1 – Preferred Reporting Items for Systematic Reviews andpatients without coagulopathy, the incidence of these
complications varies with patient factors such as prostate
size, anticoagulative medication, and procedural factors
such as the number of biopsy cores taken.
3.1.1. Hematuria
Visible hematuria following TRUS-Bx is common, with
reported rates of 10–84% [2,4,6–14]. This wide range can be
explained by different definitions for hematuria (visible
blood, need for catheterization or hospital admission),
duration, and method of data collection. In addition, higher
rates are seen in prospective studies using patient–clinician
interviews, and lower rates are seen in retrospective postal
questionnaires [15]. In a recent nested cohort study [2],
patient-reported questionnaires identified hematuria in
65.8% of patients, although it usually did not bother men
(6.2% rated it as a major or moderate problem). Within the
Rotterdam section of the European Randomized Study of
Screening for Prostate Cancer (ERSPC), hematuria lasting
>3 d was seen in 22.6% of men and correlated with prostate
(r = 0.096; p < 0.001) and transition zone volumes
(r = 0.076; p < 0.001) [16]. Others have also found
increased hematuria with larger prostate volume [17].
The influence of the number of biopsy cores on bleeding
is controversial. In 760 men, Ghani et al. found that the
prevalence of hematuria did not vary with core number
(44% with 6 cores, 41% with 8 cores, and 39% with 12 cores,
respectively) [18], while others have reported moreMeta-Analyses (PRISMA) flowchart of the search process.
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have reported that needle size (18 gauge vs 16 gauge) does
not affect bleeding rates [20–22]. Interestingly, prebiopsy
enemas were found to increase hematuria and hemoeja-
culate rates (2.5% [no enema] vs 7.9% [enema]; p < 0.001)
[17].
Although the majority of men have minor hematuria
without complications, a few develop severe hematuria
[23]. Nam et al. reported that 1.4% of 75 190 men
undergoing biopsy were readmitted within 30 d—20% for
bleeding-related diagnoses (0.3% of the entire cohort). In
contrast with infective biopsy-related complications, the
rates of bleeding problems did not change between 1996
and 2005, despite the increasing number of cores obtained
during this period. Similarly, in US Surveillance Epidemiol-
ogy and End Results (SEER)–Medicare data, admissions for
noninfectious urologic complications such as bleeding did
not increase over time [3] and were similar between initial
and repeat biopsy sessions [24]. These findings are
supported by Pinkhasov et al., who identified gross
hematuria requiring catheterization in 4 of 1000 patients
(0.4%) [6]. Dodds et al. reported admission for bleeding in
3 of 2080 patients (0.14%) [21,25]. In summary, minor
hematuria is common after prostate biopsy, while signifi-
cant bleeding requiring hospitalization occurs in <1% of
cases.
3.1.2. Rectal bleeding
As shown in Table 1, the rate of rectal bleeding varies
between 1.3% and 45% [13,14]. McCormack et al. reported
that this rate is affected by the number of biopsy cores and
use of anticoagulation but not needle size [22]. Ghani et al.
found significantly higher rates but not duration of rectal
bleeding with 8- to 10-core biopsy (26–27%) compared to
6 cores (17%) [18]. Less rectal bleeding was reported within
the ERSPC study (1.3%), and there was no correlation with
other recorded parameters [16]. Rosario et al. suggested
that rectal bleeding was more common than previously
reported (36.8%), but only 2.5% found it amajor ormoderate
problem [2]. As with hematuria, rectal bleeding is usually
perceived as minor and of little consequence by appropri-
ately counseled men. Massive rectal bleeding is uncommon
but can be life threatening. Treatment options include rectal
balloon tamponade, endoscopic adrenaline injection or
sclerotherapy, or direct vessel clipping [25–28].Table 1 – Selected studies of bleeding complications after prostate bio
First author Intervention Design
Chowdhury [19] No anticoagulation Prospective questionnai
Ihezue [40] No anticoagulation Prospective questionnai
Kariotis [36] No anticoagulation Retrospective
Raheem [72] No anticoagulation Retrospective
Chowdhury [19] LDA Prospective questionnai
Kariotis [36] LDA Retrospective
Raheem [72] LDA, warfarin, clopidogrel, LMWH Retrospective
Chowdhury [19] Warfarin Prospective questionnai
Ihezue [40] Warfarin Prospective questionnai
LDA = low-dose aspirin; LMWH = low-molecular-weight heparin.3.1.3. Hematospermia
The reported rate of hematospermia varies widely among
studies (1.1–93%) [8]. This variation may reflect cultural
issues, social stigma, or different perceptions of importance
as well as differences in data collection among studies
(timing andmethod of assessment). Rosario et al. found that
nearly all men reported hematospermia (92.6%) during the
35 d after biopsy. Unlike other hemorrhagic problems,
around one in four men perceived this as concerning or
alarming [2].
Manoharan showed the decline in hematospermia over
time from84% inweek 1 to 66% inweek 2 and 32% after 4wk
[29]. Hematospermia was associated with anxiety and a
reduction in sexual activity and resolved after a mean of
eight ejaculations. Lee et al. reported hematospermia in
21%, with a median duration of 20 d [30], while others
reported a higher frequency (60%) but shorter average
duration (12.8 d) [31]. In the ERSPC study, hematospermia
was reported by 50.4% and was correlated with age
(r = 0.228; p < 0.001), prostate volume (r = 0.058;
p < 0.001), and previous transurethral resection of the
prostate (TURP; r = 0.109; p < 0.001) [16]. The number of
biopsy cores is also associated with hematospermia. For
example, one study of Berger et al. reported hematospermia
in 31.8% of cases of 6-core biopsies, 37.4% of 10-core
biopsies, and 38.4% of 15-core biopsies (p < 0.001) [32].
3.1.4. Anticoagulation
One contentious area is the discontinuation of antic-
oagulation before biopsy (Table 1), which involves a balance
of risks between cardiovascular or thromboembolic events
when stopping anticoagulation versus the risk for bleeding
and associated complications with continuation. Patient
factors modify the precise balance of risks and benefits. For
example, men using warfarin anticoagulation for metal
heart valves are at high risk of thromboembolic events
compared with those taking preventative low-dose aspirin.
Various reports have described bleeding complications
in men with warfarin and aspirin (Table 1). For example,
two series from the same institution in which full antic-
oagulation was continued during biopsy did not show a
higher rate of self-reported bleeding complications in men
receiving anticoagulation. Giannarini et al. prospectively
assigned 196 men to continue aspirin, replace it with low-
molecular-weight heparin or discontinue aspirin withoutpsy
Men, no. Hematuria, % Hemoejaculate, % Rectal bleeding, %
re 617 37.0 13.8 11.5
re 902 60.2 21.0 13.0
282 60.6 86.9 25.9
98 63.0 10.0 39.0
re 217 33.8 12.0 14.4
152 64.5 90.1 33.6
91 46.0 6.0 40.0
re 69 27.9 7.4 13.2
re 49 36.7 8.2 14.3
E U RO P E AN URO L OGY 6 4 ( 2 0 1 3 ) 8 7 6 – 8 9 2 879replacement for TRUS-Bx. There was no difference in the
overall bleeding rate (including hematuria, rectal bleeding,
and hemoejaculate) among groups (78.5%, 69.7%, and 81.5%,
respectively; p = 0.26). Although no severe bleeding
complications occurred, men on anticoagulation reported
bleeding for a longer duration. The authors concluded that
aspirin did not increase mild bleeding but did prolong its
duration [33], as found in other reports [34–36]. Interest-
ingly, prostate biopsies have even been reported in a small
series of hemophiliacs with proactive hemostatic manage-
ment, with no major bleeding complications or clot
retention during overnight observation [37].
A systematic review andmeta-analysis of aspirin use and
bleeding following TRUS-Bx found higher rates of hematu-
ria with anticoagulation. In total, 3218 men were identified
in reports from 1990–2011, and the risk of hematuria
increased 1.36-fold with aspirin use (95% confidence
interval [CI], 1.13–1.64; p = 0.001) [38]. This increased risk
was caused by minor bleeding, although it should be noted
that most studies were not powered to assess the rare event
of severe hemorrhage. Rectal bleeding (1.24, 95% CI 0.80–
1.93) and hemoejaculate (odds ratio [OR]: 1.52; 95% CI,
0.75–3.08) were not statistically increased. The authors
concluded that continuing aspirin did not increase the risk
of moderate and severe hematuria after TRUS-Bx, so
stopping aspirin was unnecessary. Another recent review
reported a pooled OR of 0.89 (95% CI, 0.45–1.76; p = 0.73) for
bleeding complicationswith antiplatelet withdrawal versus
continuation [39]. Thus, it is likely that TRUS-Bx is safe
without stopping aspirin, because the frequency of bleeding
complications is low [40,41]; however, the data on warfarin
and clopidogrel are more limited for drawing conclusions
[13,42]. With warfarin, an additional consideration is its
interaction with antimicrobials frequently used for biopsy
prophylaxis, necessitating careful monitoring of the inter-
national normalized ratio or substitution of an alternate
antibiotic [43].
3.1.5. Reducing bleeding rates
Few authors have evaluated methods to reduce bleeding
after TRUS-Bx, including the use of pressure [44]. Kilciler
et al. reported that routine rectal balloon catheter
tamponade did not alter hematuria or hemoejaculate rates
but did reduce rectal bleeding from 17.7% to 1.5% [45]. Park
and Kim evaluated ultrasound-guided pressure (mean
duration: 3 min) upon the needle tracts immediately after
biopsy [6]. No comparison arm was available, and bleeding
rates appeared similar to those reported elsewhere without
this intervention. When severe bleeding does occur, bed
rest, fluids, and blood products may be required [13].
3.2. Infection
Infection is a well-established risk of TRUS-Bx [46], which is
among the urologic procedures with the best evidence
supporting antimicrobial prophylaxis [47]. A Cochrane
review showed that antibiotic prophylaxis significantly
reduces bacteriuria, bacteremia, fever, urinary tract infection
(UTI), and hospitalization [48]. A separate meta-analysissimilarly concluded thatantimicrobialprophylaxisdecreases
bacteriuria [49]. Professional organizations recommend
routine antimicrobial prophylaxis for TRUS-Bx [50]. A recent
international survey reported that 98.2% of men undergoing
biopsy in 84 countries received antimicrobial prophylaxis,
with fluoroquinolones most commonly prescribed (92.5%)
[51]. Although the reported duration of use varies widely
[52], most show no significant benefit from durations 24 h
[53–57]. Many additional studies support that a single dose
of antibiotics may be sufficient [58–61].
Despite these efforts, a risk of infectious complications
after biopsy remains. These complications range from
asymptomatic bacteriuria, UTI, and epididymitis to more
severe infections like meningitis [62], vertebral osteomye-
litis [63], sepsis [6,23], and septic shock [64,65].
3.2.1. Incidence of infectious complications
The frequency of infection varies among studies, withmost
studies reporting hospitalization in 0–6.3% [13,66,67].
Among 72 500 biopsies in the United Kingdom, 2.15–3.6%
were readmitted with infectious complications [68]. In the
Global Prevalence Study of Infections in Urology, 3.5% had
febrile UTI, and 3.1% required hospitalization after biopsy
[51], similar to the 3.06% frequency of sepsis reported by
Simsir et al. [69].However, other series fromNorthAmerica
and Brazil reported lower rates of sepsis (0.6% and 1.7%,
respectively) [12,70]. One Asian study reported fever in
0.5% of cases but no increase in C-reactive protein or white
blood cell count after biopsy [71], while another Asian
study reported no septic complications [72]. Studies from
Turkey [60] and Italy [64] reported approximately 2%
hospitalizations after biopsy. In the United Kingdom,
Rosario et al. reported a higher rate of 17.5% fever based
on questionnaires, with 5.5% considered a major or
moderate problem [2].
Recent studies have suggested an increase in antimicro-
bial and particularly fluoroquinolone resistance [66].
Correspondingly, most studies have shown an increase in
infectious complications after prostate biopsy over time
[3,4,25,66]. A large series from US SEER–Medicare reported
that men undergoing biopsy were 2.26 times more likely to
be hospitalized for infectious complications within 30 d
compared with randomly selected controls [3]. There was a
significant increase in hospitalizations for infection from
1991 to 2007. A follow-up study from the same group
showed that the risk of infectious complications was similar
between the initial and repeat biopsy sessions; however,
the cumulative risk of experiencing an infection increases
with a greater number of procedures [24]. Simsir et al.
similarly found no difference in sepsis risk between the
initial and repeat biopsies [69].
Nam et al. reported a rise in urologic complication rates
amongst 75 190 men undergoing TRUS-Bx in Canada
between 1996 and 2005 [4]. The 30-d hospitalization rate
rose from 1.0% in 1996 to 4.1% in 2005 ( p < 0.0001), and
72% were for sepsis. A more recent study from Canada
reported an increase from 0.52 infections per 100 biopsies
in 2002–2009 to 2.15 per 100 biopsies in 2010–2011
( p < 0.001) [73].
Table 2 – Studies on risk factors for fluoroquinolone resistance or
infectious complications after prostate biopsy
Risk factor Reference
Patient-related:
Comorbidities [3]
COPD [73]
Heart valve [78]
Diabetes [69,73,74,76,184]
Benign prostate enlargement [69,74]
Nonwhite race, Asian [3,95]
Foreign travel [185]
Recent urogenital infection [186]
Recent antibiotics, particularly ﬂuoroquinolones [75,81,185,187]
Recent hospitalization [73]
Physician/hospital employee [188,189]
Presence of a catheter [69]
Positive prebiopsy urine culture [158]
Procedure-related:
More biopsy cores [69,83,158,173]
Repeat biopsy [4,24,69]
Contaminated ultrasound gel [190,191]
COPD = chronic obstructive pulmonary disease.
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fever after 4.2% of prostate biopsies, although only 0.8%
were hospitalized [74]. As in the United States and Canada,
there was a significant increase in hospitalizations from
1993 to 2010. Most reported infectious complications result
from Escherichia coli, with high rates of resistance to
fluoroquinolones as well as ampicillin and sulfamethoxa-
zole-trimethoprim [1,74–76]. Interestingly, bacteremia
following prostate biopsy was more likely to require
admission to the intensive care unit compared with other
inciting reasons [1].
Fluoroquinolone resistance has increased globally [77],
and the presence of fluoroquinolone-resistant organisms on
rectal swab culture is a significant predictor of infection
after prostate biopsy [78]. Other studies on patient-specific
and procedural risk factors for fluoroquinolone-resistant
organisms or infectious complications are summarized in
Table 2.
3.2.2. Reducing infectious complications
Various strategies to reduce infectious complications have
been explored, as were recently reviewed [13,79]. One
strategy is rectal cleansing with povidone-iodine prior to
TRUS-Bx. Gil-Vernet reported 0.2% E. coli epididymitis using
this approach, which was lower than many other series in
the literature [80]. Abughosh et al. randomized men to
povidone-iodine cleanse versus no cleanse, with similar
rates of infection (2.6% vs 4.5%; p = 0.15) [81]. Zaytoun et al.
also found no difference in complications with enemas [17],
while Park reported a lower frequency of infectious
complications with rectal prep than without it (0.3% vs 6%)
[82], as did Jeon (OR: 0.143; p < 0.001) [83]. Overall, a
Cochrane review concluded that enema plus antibiotics
reducedthe riskofbacteremia (relative risk [RR]: 0.25; 95%CI,
0.08–0.75) compared with antibiotics alone, although there
were no differences in fever or infection [48].
Many studies have investigated switching or expanding
the antimicrobial regimen, performing rectal swab cultures,and using different techniques for biopsy. For example,
several centers using amoxicillin-clavulanate reported a
reduction in infections by adding ciprofloxacin [84] or
switching to ciprofloxacin plus or minus cefoxitin [85,86].
Conversely, switching from ciprofloxacin to coamoxiclav
and gentamicin was actually associated with increasing
infections, highlighting the importance of monitoring
patient outcomes following changes in protocol [87]. Adibi
et al. compared 290 men undergoing biopsy with 3 d
of trimethoprim-sulfamethoxazole or ciprofloxacin to
310 later TRUS-Bx with the addition of gentamicin and
found a decreased frequency of hospitalization in the later
group (from 3.8% to 0.6%) [88]. Others have reported good
results adding gentamicin [89], amikacin [90], or isepamicin
[71]. Yamamoto reported a similar frequency of infections
using tosufloxacin (4.8%) compared to levofloxacin prophy-
laxis (5%) [91]. Another study reported that mixing 1 gram
of ceftriaxone into the periprostatic lidocaine injection was
associated with less sepsis [92].
Disadvantages of augmented prophylaxis include possi-
ble increases in side effects or cost. However, Adibi et al.
showed that as the cost of hospital admission increases,
using more intensive prophylaxis becomes more cost-
effective [93]. However, a drawback is potentially increas-
ing future antimicrobial resistance.
Alternatively, investigation is ongoing into the use of
targeted prophylaxis. A rectal swab is performed at the visit
preceding prostate biopsy and is plated on MacConkey agar
containing ciprofloxacin. Patients with ciprofloxacin-
sensitive bacteria can then receive ciprofloxacin prophy-
laxis, while culture results can guide an alternative
selection for those with resistance. Although a positive
rectal swab culture is a risk factor for TRUS-Bx infection
[81,94], the presence of resistant organisms does not
necessarily translate into clinical infection [95]. In fact,
prevalence studies from several countries have shown
fluoroquinolone-resistant organisms in 14–25% of rectal
swab cultures, but only a small proportion of these patients
actually develop clinical infection [76,78,94–98].
A few nonrandomized studies have examined the results
of targeted prophylaxis. Duplessis et al. gave ciprofloxacin
prophylaxis to all men except those with positive rectal
swab cultures, who instead received targeted prophylaxis,
and there were no infectious complications [97]. Taylor
et al. reported a nonsignificant decrease in the frequency of
sepsis using a targeted approach, compared with other
patients receiving standard prophylaxis (0% vs 2.6%; p = 0.12)
[96]. To date, there are no randomized studies showing that
targeted prophylaxis using rectal swabs results reduces
infection and cost compared with standard or expanded
prophylaxis.
Finally, several studies have assessed whether technical
modifications influence infection rates. For instance,
transperineal biopsy has been suggested as a possible
alternative way to perform the technique, although Shen
et al. did not find any qualitative difference in infection rates
in a secondary analysis of studies on transrectal versus
transperineal biopsy [5]. Some technical aspects were not
associated with infectious risk, such as needle size [22] or
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[11]. Tuncel et al. reported fewer infectious complications
with a disposable needle guide (p < 0.0001) [99], while
others found no difference in bacteriologic or symptomatic
UTIs with disposable versus reusable needle guides [100].
However, adequate reprocessing/disinfection of reusable
needle guides and biopsy probes is critical [101–103].
Infectious complications after biopsy are an increasing
issue, and numerous strategies are being evaluated to reduce
this risk. As investigation in this area evolves rapidly, general
recommendations include a thorough history and physical
examination, including assessment of risk factors for
resistant bacteria and infection (see Table 2). In the future,
improved markers and imaging may reduce invasive biopsy
procedures for many patients [104]. For men with signs or
symptoms of infection after biopsy, prompt evaluation,
including cultures, is recommended. Broad-spectrum anti-
biotics should be given (eg, Amikacin or carbapenems), and
later tailored based on culture data [13,105].
3.3. Pain
Prebiopsy analgesia was not always routinely used for
sextant TRUS-Bx [106,107]. However, TRUS-Bx is associated
with significant pain, discomfort, and anxiety in a propor-
tion of men [108], which is associated with an unfavorable
attitude to rebiopsy [2]. For example, a Finnish study
reported that 18% of men would not accept a repeat biopsy
[109]. With many men ultimately requiring rebiopsy and
greater sampling performed, effective painmanagement for
TRUS-Bx is paramount [110,111].
3.3.1. Measures of pain
Most studies assessed pain using the visual analog scale
(VAS; 0 = none to 10 = worst pain) or a five-point scale
during different steps (probe insertion, periprostatic
infiltration, and biopsy sampling) and less commonly after
biopsy [31,112,113]. When evaluating studies using the
VAS, it is important to consider whether the change is
clinically meaningful (eg, >2 points). Other instruments
used to evaluate biopsy pain include the verbal response
scale; the Multidimensional Personality Questionnaire; the
State-Trait Anxiety Inventory; and physiologic parameters
such as blood pressure, heart rate, respiratory rate, or serum
cortisol levels [114,115]. Patients with higher levels of
anxiety based on these evaluations may require a higher
level of anesthesia.
3.3.2. Managing pain
Numerous factors contribute to pain at biopsy, including
anxiety [115,116], which may be greater in young patients
but was unrelated to other prostate cancer (PCa) risk factors
(such as PSA and positive family history) [117]. Some
authors have therefore proposed anxiety-reducing instru-
ments (eg, music) to mitigate perceived pain [118].
More painwas reportedwhen a periprostatic injection of
ceftriaxone was included [92]. However, it does not appear
that using 16- versus 18-gauge needles affects pain [21,22].
Other predictors of pain include anorectal compliance,prostate volume, number of biopsy cores, and younger age
[115,119–122]. As such, several studies have reported
greater added value for anesthetic agents in younger men
[120,121]. Kilciler et al. evaluated patient positioning and
found slightly less pain in left lateral decubitus than
lithotomy, although the difference may not be clinically
meaningful (score 2.72 vs 4.02) [123]. In summary,
selection of anesthesia for biopsy should take into
consideration the patient’s tolerance to pain, anxiety, and
sociocultural factors [107,124,125].
With respect to the type of anesthetic agent, nitrous
oxide has been shown to be effective [126]; however, in an
underpowered comparison with periprostatic lidocaine
injection, no significant difference was found [127].
Although the precise mechanism of pain reduction is
uncertain, action on opiate receptors in the spinal cord
and muscle relaxation may contribute to its effect.
The use of sedoanalgesia has also been described by
several groups and was recently reviewed [128]. Although
highly effective [129,130], its use remains somewhat
cumbersome for outpatient practice and requires monitor-
ing, which increases cost [131]. Nevertheless, for selected
patients, including those with excessive anxiety or local
anorectal conditions, it remains a viable option.
The use of saddle analgesia has been shown to be
effective in reducing pain associated with biopsy and
improving acceptability [132,133]. Several studies have
compared this technique with periprostatic nerve blockade
with variable findings, precluding definitive conclusions.
Periprostatic nerve blockade (PPNB) itself appears to be
safe [134], and 10–20 cm3 of lidocaine significantly reduces
pain compared to no anesthetic agent [135–138]. Several
technical modifications of PPNB have also been described,
including apical infiltration, basal infiltration, and combi-
nation techniques [139–142]. A recent study found no
significant difference in surgical complexity among men
who received PPNB [143]. Numerous studies have exam-
ined intrarectal creams, gels, and lidocaine suppositories. A
Spanish study reported that biopsies performed with rectal
only lidocaine gel were generally well tolerated [119].
Although these agents in some studies were more effective
thanplacebo,most studieshave shownthat local gels achieve
inferior analgesia compared with PPNB [130,144–147]. That
finding notwithstanding, numerous studies have demon-
strated the efficacy of combining intrarectal local anesthetic
agents or analgesics with PPNB, particularly to reduce the
pain resulting from probe insertion and the periprostatic
infiltration itself [122,148–150]. Strong evidence exists for
employing some form of anesthetic agent to reduce pain at
biopsy, but most of the comparative studies have been
underpowered.Theprecise combinationof techniquescanbe
tailored to the individual patient, local circumstances, and
individual expertise.
3.4. Lower urinary tract symptoms and urinary retention
A low risk of acute urinary retention exists after standard
TRUS-BX, ranging from 0.2% to 1.7% [6,8,12,17,31,32,61,
151–156]. Retention is usually transient, and most patients
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risk of short-term worsening of voiding complaints after
TRUS-Bx [157]. Reported ratesofdysuria typically range from
6% to 25% [15,30,109,158].
No convincing evidence exists that the number of biopsy
cores affects risk of urinary retention [32]. The impact of
serial biopsies has not been well studied. A cohort of
333 men undergoing active surveillance found no correla-
tion between the number of biopsies and International
Prostate Symptom Score (IPSS) [159]. However, Raaij-
makers et al. reported that prostate volume, ratio of
transition zone volume to total prostate volume, and a
higher IPSS are associated with risk of urinary retention
after prostate biopsy [16]. Similarly, Zaytoun et al. showed
that increasing prostate size predicted retention after
biopsy (OR: 4.45; 95% CI, 2.01–9.84; p < 0.001) [17].
There has also been investigation of a-blockers to
prevent urinary problems following biopsy. A prospective
study randomized 66 consecutive patients undergoing 12-
core TRUS-Bx to 30 d of tamsulosin versus no tamsulosin
[160]. Compared to baseline, tamsulosin was associated
with a significant reduction in IPSS and increase in
maximum flow rate as compared to worse voiding
parameters at day 7 in controls.
In summary, the data suggest a low (<2%) overall risk of
urinary retention, although 25% of patients experience
transient worsening of LUTS after TRUS-Bx. Although
premedication is not necessary for the majority, peripro-
cedural a-blockers could be considered for patients with
severe symptoms or large prostates to reduce the risk of
urinary retention.
3.5. Erectile dysfunction
There is concern that prostate biopsy, especially if repeated
or extensive, may lead to ED. However, the data on this are
sparse and heterogeneous, with significant confounders.
Reasons for heterogeneity among studies include intermix-
ing initial with repeat TRUS-Bx and lack of adjustment for
prebiopsy potency. Most studies on biopsy and erectile
function included 62–100 patients followed for 1 wk to 1 yr
(Table 3a) [161]. In general, there seemed to be a trend
toward increasing ED at 1 mo, with five studies demon-
strating statistically significant changes in rates of mild to
severe ED. Longer follow-up showed that these changes
resolved back to baseline. One study demonstrated a trend
toward higher ED rates when using periprostatic local
anesthetic nerve blocks (p = 0.055) [162]. One study
demonstrated that sexual dysfunction can also occur in
female partners of men undergoing TRUS-Bx at 1 and 6 mo,
despite male function improving at 6 mo [163].
Three studies evaluated ED with repeat biopsies during
active surveillance (Table 3b) [159,164,165]. One prospec-
tive study using the International Index of Erectile Function
(IIEF-5) in 427 active surveillance patients reported changes
in sexual activity level for >20% of respondents during
3.2-yr median follow-up [165]. Adjusted erectile function
scores were not associated with biopsy exposure cross-
sectionally or longitudinally.Conversely, a different cohort of 333 men undergoing
active surveillance found a correlation between increasing
biopsy number and decreases in IIEF-5 score (p = 0.04)
[159]. Multivariable analysis for biopsy number, age,
prostate volume, and PSA showed that only biopsy number
was associated with decreasing Sexual Health Inventory for
Men score ( p = 0.02). A limitation of studies performed in
active surveillance populations is potential selection bias
resulting from progression or reclassification, with subse-
quent treatment in some men.
It is also noteworthy that there is a strong psychogenic
impact of knowing one has PCa that can also contribute to
ED. A prospective study of 85 men who underwent a single
12-core TRUS-Bx found no significant differences in pre-
and postbiopsy IIEF-15 scores (57.8 [SD 12.9] vs 54.3 [SD
17.2]), butmenwith biopsy-proven cancer had significantly
greater changes in postbiopsy IIEF compared to men
without cancer (10.1 vs 1.0; p < 0.001) [161], including
deteriorations in sexual desire, orgasmic function, inter-
course satisfaction, and overall satisfaction.
One prospective evaluation attempted to reduce the
confounder of PCa as a cause of ED by examining baseline,
1-, and 6-mo IIEF questionnaires for 88 patients who had
negative saturation biopsies (median 22 cores) [166].
Patient age, serum PSA levels, prostate volumes, and
number of cores showed no significant correlation with
changes in IIEF scores. According to the IIEF-5, for
previously potent cancer-free patients, 11.6% reported mild
to moderate ED at the first month, which decreased to 0% at
6 mo. Thus, although IIEF-5 and IIEF-Erectile Function
domain scores significantly declined from baseline to the
first month, there was no difference by 6 mo.
Another prospective single-center study of 46 men who
underwent a median of nine biopsy cores found that 6.52%
and 4.34% reported biopsy-attributable ED 1 and 3mo later,
respectively [167]. In this study, 61% of men had a prior
biopsy, and 30.4% had PCa detected. PCa diagnosis, prostate
size, and number of cores were not significantly associated
with ED. Rarely, more severe complications have been
reported, including a case of Mondor’s disease and high-
flow priapism [168].
It appears that even the evaluation for PCa and concerns
about elevated PSA may affect sexual function. A cross-
sectional telephone survey showed that 109 men with
negative biopsy were more worried about PCa, and 19%
hadmoderate to big problemswith sexual bother compared
to 10% of age-matched primary care patients with a
PSA <4 ng/ml [169].
Overall, the exact etiology of erectile problems following
prostate biopsy is unknown. Temporary inflammatory and
neurovascular damage are likely important, possibly
combined with the impact of PPNB. Furthermore, the
impact of anxiety and psychological factors is relevant, with
some studies showing increased anxiety at the time of
screening, biopsy, and immediately following biopsy [170].
In summary, if there is an impact of biopsy on erectile
function, it appears to be relatively minimal and often
transient [157]. The data on ED from multiple biopsies
during active surveillance are more difficult to interpret,
Table 3 – Erectile dysfunction rates in men undergoing (a) transrectal biopsies and (b) active surveillance
(a)
First author No. biopsied
(evaluated/
total biopsied)
Type of
biopsy
No. of
biopsy cores
(range)
Follow- up Instrument Deﬁnition D ED rate PDE5-I use
Chrisofos [167] 46 TRUS-Bx Median: 9 (6–12) 1–3 mo IIEF-5 Mild to sev 0: 82.6%
1 mo: 91.3% ( p = 0.216)
3 mo: 89.1% ( p = 0.726)
NR
Stravodimos [192] 62
RCT:
1. Without nerve block
2. With lidocaine PPNB
TRUS-Bx NR 10 d and 20 d IIEF-15-EF Mild to sev
(EF domain
0: 6.6% vs 6.2%
10 d: 21.4% vs 16.6%
20 d: 7.1% vs 3.3%
(not statistically signiﬁcant;
p value: NR)
NR
Akbal [166] 74/150
(75/150 had previous
biopsy)
Saturation
transrectal
Median 22 (20–30) 1 mo and 6 mo IIEF-5 Mild to sev 0: 42%
1 mo: 49% ( p = 0.04)
6 mo: 41% ( p = 0.14)
NR
Aktoz [193] 62/90
RCT:
1. Diclofenac suppository
2. Levobupivacaine
3. Diclofenac suppository
plus levobupivacaine
TRUS-Bx 10 1 mo and 3 mo IIEF-5 Mild to sev 0: 85.5%
1 mo: 88.7%
3 mo: 88.7%
(p = 0.82)
NR
Akyol [194] 136 TRUS-Bx NR 6–12 mo None NR 1 mo: 2.2% (3/136)
6–12 mo: 0%
(p value NR)
NR
Tuncel [163] 97 (and female partners) TRUS-Bx NR 1 mo and 6 mo IIEF-5
Female Sexual
Function Index
for female partners
Mild to sev 0: 52.6%
1 mo: 72.2%
6 mo: 59.8%
(p < 0.001)
Female Sexual Function
Index scores: signiﬁcantly
lower at 1 mo and
6 mo ( p < 0.001)
NR
Turgut [195] 200 TRUS-Bx NR 1 mo Physician reported ED 1 mo: 0% NR
Klein [162] 198
RCT:
1. Without PPNB
2. With PPNB
TRUS-Bx 10 in biopsy naı¨ve;
20 in previous negative
biopsy
1 wk, 4 wk, 12 wk IIEF-5 Mild to sev Group 1
0: 70.5%
1 wk: 86.4% (p = 0.119)
4 wk: 86.4% (p = 0.119)
12 wk: 77.3% (p = 0.628)
Group 2
0: 63.9%
1 wk: 86.1% (p = 0.055)
4 wk: 66.7% (p = 0.811)
12 wk: 63.9% (p = 1.00)
NR
Helfand [161] 85/134 TRUS-Bx 12 1–48 wk IIEF-15 Change in
IIEF-15 sco
3.5 (SD: 11.8)
Positive biopsy best predictor
of ED (OR: 9.16) on multivariate
analyses
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E U R O P E AN URO LOG Y 6 4 ( 2 0 1 3 ) 8 7 6 – 8 9 2884given that all of these men have PCa and that aging during
the years between biopsies may have independently led to
worsening ED.
3.6. Morbidity following transperineal prostate biopsy
Transperineal biopsy is increasingly popular as a means for
accurate diagnosis and risk stratification. It is often used in
men with a prior negative TRUS-Bx and persistent risk for
PCa or those with low- to intermediate-risk disease electing
active surveillance or focal therapy. Burden to the patient
and health care system has been raised as a concern
affecting the dissemination and diffusion of this technique.
Some groups are also using transperineal templatemapping
biopsies, which fixes the systematic error of standard TRUS-
Bx to a 5-mm sampling frame [171] as a tool to validate
novel imaging techniques such as multiparametric mag-
netic resonance imaging, as it can be applied to all men at
risk and thus minimizes selection bias [172].
Reports on the role of transperineal biopsies have varied
in the technique used. Some have used sector biopsies,
in which a full 5-mm sampling is not conducted but
1–2 biopsies are taken from predefined sectors. Others have
limited the total number of transperineal biopsies to 14, 22,
or 36 regardless of prostate size [173–175]. Two reports
from the same group used a combination of TRUS biopsy
and template mapping 5-mm sampling in men who were
suitable for active surveillance [176,177].
Table 4 shows the results of identified studies on the
complications of transperineal biopsy. UTI varied between
0% and 1.6% in the 12 of 24 series reporting on this outcome,
with no instances of sepsis. Prolonged or severe hematuria
requiring admission or catheterization was reported in
12 series and varied between 0% and 5.2%, with most
showing no significant hematuria. Transient and mild
hematuria was reported in three series in between 36.7%
and 100%. Acute urinary retention was reported in 1.6–8.8%
of cases. One outlier reported 20.6% urinary retention (7 of
34 men) but did not routinely use perioperative a-blockers,
as was standard in all other series [178]. Overall, compara-
tive studies have failed to demonstrate any significant
differences in the rate of complications between transrectal
and transperineal biopsies [5,179].
3.7. Mortality
Mortality after prostate biopsy is extremely rare, and most
reported deaths are the result of septic shock [180]. Lethal
Fournier’s gangrene has also been reported [64,69,181].
Bleeding postprocedure is usually self-limiting and rarely
life threatening (see previous section).
A few larger studies have attempted to examine
mortality rates associated with prostate biopsy. One
population-based study compared mortality between
22 175 patients who underwent prostate biopsy with
1778 age-matched controls [182]. Overall 120-d mortality
after biopsy was 1.3% versus 0.3% (p< 0.001) in controls. Of
men 60 yr of age, 0.2% died within 120 d versus 2.5% of
men 76–80 yr of age. A higher Charlson Comorbidity Index
Table 4 – Morbidity following transperineal prostate biopsies
First author Sample, n No. of biopsy
cores
Infection,
no. (%)
Acute urinary
retention,
no. (%)
Signiﬁcant
hematuria,
no. (%)
Other, no. (%)
Pinkstaff [196] 210 Mean: 21.2 (12–41) 0 (0) 24 (11) 11 (5.2) –
Satoh [175] 128 22 1 (0.8) 2 (1.6) NR ‘‘Difﬁcult urination’’: 2 (1.6)
Demura [197] 371 Mean: 20  4 0 (0) 6 (1.6) 1 (0.3) Hematospermia >1 mo: 1 (0.3)
Bott [198] 60 Median: 24 (18–36) 0 (0) 2 (3.3) 1 (1.7) NR
Moran [199] 180 Mean: 41.3 (13–117) NR 10 (4.5) 12 (5) NR
Barzell [176] 80 (66 combined
with repeat
systematic TRUS-Bx)
Mean: 66 (20–138) 1 (1.3) 5 (6.3) 1 (1.3) Perineal ecchymoses: 2 (2.6)
Scrotal hematoma: 1 (1.3)
Li [152] 303 Mean; 23.7 (11–44) 0 (0) 7 (2.3) 0 (0) Hematuria (mild and
transient): 107 (45.3)
Merrick [200] 102 Median: 50 NR 9 (8.8) 1 (1.0) NR
Merrick [201] 129 Median: 56 NR 11 (8.7) 1 (0.8) IPSS deterioration: resolution
by 30 d
No rectal problems
EF (IIEF-6): 3 (4.6); IIEF-5: 12
(in those with score 13)
Taira [202] 373 Mean: 54 0 (0) NR NR IPSS:
Baseline 10.4
7 d: 4.6
30 d: 3.8
No ED (physician reported)
Yan [203] 656 Median: 22 0 (0) 13 (2.0) 0 (0) Hematuria mild and
transient: 241 (36.7)
Galfano
(abstract) [174]
126/378 biopsied 14 NR NR NR ED (IIEF-5) at 1 mo: no statistically
signiﬁcant change in scores
17.6% without ED reported
mild ED at 1 mo
Ayres [204] 101 Mean: 47  14.5 NR NR NR NR
Pal [173] 40 36 0 (0) 1 (2.5) 0 (0) Hematospermia common
Patel [205] 539 Mean: 55.1  11.8 NR NR NR NR
Barqawi [206] 180 Median: 56 (8–124) 0 (0) 9 (4.2) 0 (0) Hematuria (mild transient): all
Transient orthostatic
hypotension: 11 (5.1)
Taira [207] 64 Mean: 58.5  6.3 0 (0) 3 (4.7) NR NR
Gershman [178] 34 Mean: 24.8  7.8 NR 7 (20.6)
(no perioperative
a-blockers)
NR NR
Hossack [208] 1132 (correlation
with prostatectomy)
Mean: 23 (13–43) NR NR NR NR
Huo [209] 414 (correlation
with prostatectomy)
Median: 22  5.7 NR (4.5) NR NR
Mabjeesh [210] 92 Mean: 30 (24–54) NR NR NR NR
Barzell [177] 124 Mean: 90 1 (0.8) 4 (3.2) 2 (1.6) LUTS: 2 (1.6)
Scrotal hematoma: 1 (0.8)
Kasivisvanathan
[211]
182 (correlated with
multiparametric MRI)
Mean: 44.6 Sepsis: 0 (0)
UTI: 3 (1.6)
5 (2.7) 2 (1) Perineal ecchymoses: all
(self-resolving)
Transient ED: 0 (0)
Crawford [212] 25 (correlation
with prostatectomy)
Median: 49 (27–110) NR NR NR NR
Arumainayagam
[213]
64 (correlation with
multiparametric MRI)
34.0 (IQR: 29.0–40.8) NR NR NR NR
NR = no result; TRUS-Bx = transrectal ultrasound–guided biopsy; IPSS = International Prostate Symptom Score; EF = erectile function; IIEF = International Index
of Erectile Function; ED = erectile dysfunction; LUTS = lower urinary tract symptoms; MRI = magnetic resonance imaging; UTI = urinary tract infection; IQR =
interquartile range.
E U RO P E AN URO L OGY 6 4 ( 2 0 1 3 ) 8 7 6 – 8 9 2 885(CCI) score was also associated with increasing mortality,
with 0.7%, 1.2%, and 2.2% mortality for scores 0, 1–2, and
3, respectively. Perhaps unexpectedly, initial biopsy
procedures carried a higher mortality risk than subsequent
procedures (1.4% vs 0.8% vs 0.6% for first biopsy, second
biopsy, and three or more biopsies). On multivariable
analysis, age, CCI score, and total number of biopsyprocedures represented independent predictors of mortali-
ty. Although this study did not explain the cause of death, it
does suggest that careful consideration of life expectancy
should be factored into biopsy decisions.
In Canada, Nam et al. reported a 0.09% 30-d mortality
rate after biopsy [4]. In the ERSPC, 11 721 men who
underwent TRUS-Bx had a significantly lower risk of 120-d
E U RO P E AN URO LOG Y 6 4 ( 2 0 1 3 ) 8 7 6 – 8 9 2886age-adjusted other-cause mortality (RR: 0.41; 95% CI,
0.23–0.73; p = 0.002) compared to screen-negative men
[183]. A later study about infectious complications in the
ERSPC Rotterdam section reported no biopsy-related deaths
[74], as is the case in other major biopsy series [134].
Similarly, in US SEER–Medicare data, 55 men (0.31%) who
underwent biopsy died within 30 d compared with 1474
controls (1.09%) [3]. On multivariable analysis adjusting for
age, race, SEER region, year, and CCI score, biopsiedmen had
a markedly lower 30-d mortality rate compared with
controls (OR: 0.29; 95% CI, 0.22–0.38; p< 0.0001). However,
menwhowere hospitalizedwith an infectious complication
had a 12-fold greater 30-d mortality rate compared with
those who were not (95% CI, 8.59–16.80; p < 0.0001).
Overall, this suggests that men being selected for biopsy
are generally healthier than the general population, and
biopsy itself has an exceedingly low risk of fatal complica-
tions. However, patients should be counseled to seek
immediate attention for signs of postbiopsy infection to
initiate prompt management.
4. Conclusions
Bleeding is the most frequently reported complication after
biopsy, but it is usually minor and resolves spontaneously.
All men undergoing TRUS-Bx should receive antimicrobial
prophylaxis for 24 h, should be warned about the
increasing risk of infection, and told to seek promptmedical
care. The increase in fluoroquinolone-resistant organisms is
a trend that must be monitored, and tailored antibiotic
regimens may be necessary in the future. The use of
anesthetic agents can reduce the pain associated with
prostate biopsy. An exacerbation of LUTS may also occur
after biopsy, particularly in men with an enlarged prostate,
but urinary retention is infrequent. Overall, men undergo-
ing biopsy are generally healthier than the general
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